Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Transgenic expression of enhanced AsCas12a in mice enables In Vivo multiplex genetic editing and development of diverse novel models of myeloid neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJared T. Brown

Discussion

Loading...

Member takes

Overview

Transgenic expression of AsCas12a improves multiplex genetic editing in mice, suggesting advances for myeloid malignancy models.

Key Points

  • To explore the potential of enhanced AsCas12a for multiplex genetic editing in murine models of myeloid malignancies.
  • Developed transgenic enAsCas12a mice for consistent myeloid malignancy generation.
  • Utilized CRISPR techniques to identify genetic targets for malignancies in mouse hematopoietic stem cells.
  • Analyzed models using single cell RNA sequencing to determine genetic characteristics and editing efficiency.
  • Achieved average editing efficiency of 74% across key genes in human MDS/AML.
  • Generated diverse myeloid neoplasm models using multiplex genetic editing with distinct phenotypes.
  • Noted increased multiplicity of gRNA per cell in advanced neoplasm stages, enhancing model reproducibility.

Cite This Study

Jared T. Brown (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d594https://doi.org/10.1182/blood-2025-3227
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficient and multiplexed somatic genome editing with Cas12a mice2024 · 8 citations
  2. 2Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening2024
  3. 3High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics2024
  4. 4Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models2019 · 14 citations
  5. 5Human HSPCs CRISPR-engineered to endogenously express oncogenic NRAS generate a transplantable lethal myeloid malignancy targetable with novel RAS therapeutics2025